Literature DB >> 12909600

Phosphatidylcholine metabolism of rat trachea in relation to lung parenchyma and surfactant.

Gunnar A Rau1, Heike Dombrowsky, Andreas Gebert, Hubert H Thole, Horst von der Hardt, Joachim Freihorst, Wolfgang Bernhard.   

Abstract

Pulmonary surfactant prevents alveolar collapse and contributes to airway patency by reducing surface tension. Although alveolar surfactant, consisting mainly of phospholipids (PL) together with neutral lipids and surfactant-specific proteins, originates from type II pneumocytes, the contribution of airway epithelia to the PL fraction of conductive airway surfactant is still debated. We, therefore, analyzed the composition, synthesis, and release of phosphatidylcholine (PC) molecular species as the main surfactant PL of the rat trachea compared with the lung. Analyses of individual PC molecular species with HPLC and electrospray ionization mass spectrometry revealed that the rat trachea contained and synthesized much more palmitoyloleoyl-PC, palmitoyllinoleoyl-PC, and palmitoylarachidonoyl-PC, together with increased amounts of alkylacyl-PC, and less surfactant-specific species such as dipalmitoyl-PC than the lung. Organ cultures with [methyl-3H]choline as precursor of PC revealed that, in the trachea, synthesized PC was retained in the tissue, rather than secreted. [Methyl-3H]choline-labeled dipalmitoyl-PC was a negligible component in the trachea, and, in contrast to the lungs, palmitoyloleoyl-PC was enriched in tracheal secretions. We conclude that the surfactant fraction in the airways does not originate from the airways but is produced in the alveolar space and transported upward.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12909600     DOI: 10.1152/japplphysiol.01194.2001

Source DB:  PubMed          Journal:  J Appl Physiol (1985)        ISSN: 0161-7567


  1 in total

1.  Tensiometric and Phase Domain Behavior of Lung Surfactant on Mucus-like Viscoelastic Hydrogels.

Authors:  Daniel M Schenck; Jennifer Fiegel
Journal:  ACS Appl Mater Interfaces       Date:  2016-03-01       Impact factor: 9.229

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.